Multicenter retrospective and prospective European observational study. At each site, all consecutive patients with a 2016- or 2022 World Health Organization (WHO) confirmed diagnosis of myelofibrosis (MF) established from 01/01/2018 to 31/12/2027 will be enrolled into the study. Yearly follow-up updates will be scheduled until the end of data collection on 31/12/2028 or until the last available patient visit, whichever comes first. At least 1 year of follow-up will be ensured from the last patient enrolled.
Diagnosis of primary myelofibrosis (PMF) or secondary (i.e., post-ET/PV MF) myelofibrosis according to 2016- or 2022-WHO criteria ascertained between 01/01/2018 and 31/12/2027
Age ≥ 18 years
Signed informed consent where applicable, in line with current European General Data Protection Regulation (GDPR) directives
Diagnosis of early/prefibrotic primary myelofibrosis
Concurrent participation to interventional clinical trials in MF
FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
Lead sponsor
GlaxoSmithKline
Collaborator